CROMSOURCE announces launch of COVID-19 clinical trial
This trial is expected to be performed in Italy, though additional studies are planned by CROMSOURCE for other countries in Europe as well as the United States. “The
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorisation for Moderna’s Spikevax JN.1, an updated Covid-19 vaccine targeting the JN.1 variant of SARS-CoV-2.
CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing
The clinical study, dubbed COLCORONA, will assess whether colchicine will serve as an effective treatment to prevent the phenomenon of major inflammatory storm present in adults suffering from
In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH).
Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This
BioArdis will retain all rights to the licensed product in the rest of the world. BIO-1262 is being evaluated as a potential new treatment for hepatocellular carcinoma (HCC)
The FDA created the Fast Track process to facilitate the development and expedite the review of drugs to treat serious or life-threatening diseases or conditions, which have the